$BIOAF News

Last published 3y ago

3y agoBIOAFBioasis Provides Corporate Update and Announces Suspension of OperationsGlobeNewswireNEW HAVEN, Conn., June 20, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI)) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
3y agoBIOAFBioasis Provides Update on Business OperationsGlobeNewswireNEW HAVEN, Conn., March 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI)) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
3y agoBIOAFBioasis Announces AGM Results and Provides Update on Financial PositionGlobeNewswireNEW HAVEN, Conn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI)) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
3y agoBIOAFBioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plcGlobeNewswireNEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI)) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
3y agoBIOAFBioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022GlobeNewswireNEW HAVEN, Conn., Jan. 19, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI)) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
3y agoBIOAF MTPBioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of SecurityholdersGlobeNewswireNEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI)) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
3y agoBIOAF MTPBioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plcGlobeNewswireNEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI)) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
3y agoBIOAFBioasis Technologies Inc. Announces Shareholder WebinarGlobeNewswireNEW HAVEN, Conn., Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI) (OTCQB:BIOAF), (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
3y agoBIOAF MTPBioasis Technologies Inc. Announces Merger with Midatech Pharma plcGlobeNewswireNEW HAVEN, Conn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI)) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
4y agoBIOAFBioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022GlobeNewswireNEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical
4y agoBIOAFBioasis Technologies Inc. Announces Stock Option GrantsGlobeNewswireNEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal g
4y agoBIOAFBioasis Announces Filing of Its First Quarter Financial Statements and MD&AGlobeNewswireNEW HAVEN, Conn., July 29, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. ((TSX.V:BTI, OTCQB:BIOAF) (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics
4y agoBIOAFBioasis Acquires Phase 2 Ready Rare Orphan EGF AssetsGlobeNewswirePhase 2 ready assets transform Bioasis into a clinical stage company with a multi-asset pipeline focused on rare and orphan drug indications Unique approach to neurodegeneration targeting remyelination Initial indications Chronic Inflammatory Degen
4y agoBIOAFBioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&AGlobeNewswireNEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics acr
4y agoBIOAFBioasis Enters Into Research Collaboration With JanssenGlobeNewswireNEW HAVEN, CONN., U.S.A., April 11, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company or "Bioasis"), a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeuti
4y agoBIOAFBioasis to Attend and Present at Upcoming Industry ConferenceGlobeNewswireNEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics acr
4y agoBIOAFBioasis Announces $200,000 Non-Brokered Private PlacementGlobeNewswireNEW HAVEN, Conn., Feb. 17, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics acro
4y agoBIOAFBioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021GlobeNewswireNEW HAVEN, Conn., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. ((TSX.V:BTI, OTCQB:BIOAF) (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics a
4y agoBIOAFBioasis Announces Annual General Meeting ResultsGlobeNewswireNEW HAVEN, Conn., Dec. 16, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics acro
4y agoBIOAFBioasis to Attend and Present at Upcoming Industry ConferencesGlobeNewswireNEW HAVEN, Conn., Dec. 09, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics acro
4y agoBIOAFBioasis Announces Annual General Meeting DetailsGlobeNewswireNEW HAVEN, Conn., Nov. 29, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics acro
5y agoBIOAFBioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2021GlobeNewswireNEW HAVEN, Conn., Oct. 28, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the
5y agoBIOAFBioasis to Attend Upcoming Industry ConferencesGlobeNewswireNEW HAVEN, Conn., Sept. 30, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics acr
5y agoBIOAFBioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development AdvisorGlobeNewswireNEW HAVEN, Conn., Aug. 18, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the
5y agoBIOAFBioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³™ Fusion Protein Comprising Iduronate-2-sulfataseGlobeNewswireNEW HAVEN, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology to enhan
5y agoBIOAFBioasis Announces Filing of Its First Quarter Financial Statements and MD&AGlobeNewswireNEW HAVEN, Conn., July 29, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. ((TSX.V:BTI, OTCQB:BIOAF) (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3TM platform techn
5y agoBIOAFBioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program ManagerGlobeNewswireNEW HAVEN, Conn., July 20, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the
5y agoBIOAFBioasis Announces Positive Results From an Efficacy Study of xB3™-IL-1RA in a Model of Multiple SclerosisGlobeNewswireNEW HAVEN, Conn., July 07, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology to enhan
5y agoBIOAFBioasis Announces the Appointment of Dave Jenkins as Chief Financial OfficerGlobeNewswireNEW HAVEN, Conn., July 01, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the
5y agoBIOAFBioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research CollaborationGlobeNewswireNEW HAVEN, Conn. and MANCHESTER, United Kingdom, June 30, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSXV:BTI, OTCQB:BIOAF) ("Bioasis") and Oxyrane UK Ltd. ("Oxyrane") are pleased to announce the initiation of a research collaboration. Bioa
5y agoBIOAFBioasis Technologies Announces Closing of Initial C$3,000,000 Funding by Lind PartnersGlobeNewswireNEW HAVEN, Conn., June 29, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. ("Bioasis" or the "Company") ((TSX.V:BTI, OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the
5y agoBIOAFBioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&AGlobeNewswireNEW HAVEN, Conn., June 25, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for th
5y agoAGCBF AUSAF BIOAF BNCHF+16Proactive news headlines including Nextleaf Solutions, Genprex, Ready Set Gold, Sigma Lithium and Esports EntertainmentGlobeNewswireNew York , June 23, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Victory Square Technologies Inc (CSE:VST) (OTC:VSQTF) (FRA
5y agoBIOAFBioasis Technologies enters into Convertible Security Funding Agreement for Institutional Investment of up to C$10 millionGlobeNewswireNEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. ("Bioasis" or the "Company") ((TSX.V:BTI, OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the
5y agoBIOAFBioasis Announces Publication Validating its xB³ ™ Platform Technology for CNS TherapeuticsGlobeNewswireNEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI, OTCQB:BIOAF), (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the